BeiGene ups offering to a whopping $750M; Celgene backing $475M raise for Agios; Avastin copycat OK'd for Europe
→ In a demonstration of its popularity, BeiGene $BGNE has priced its public offering at $750 million — quite a bit more than the $650 million it had proposed earlier in the week. A promising candidate for investors looking to get in on emerging Chinese companies, the biotech is hard at work with several checkpoint drugs, one of which it’s developing with partner Celgene $CELG. It plans to use the money for general purposes, including research and development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.